Name: Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9
SKU: 16061
Availability: InStock

Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9

€550 – €2500

Remdesivir triphosphate is synthesised by Santiago Lab (Prague, Czech Republic).

We are providing Remdesivir triphosphate in the form of Na⁺ salt or Et₃N⁺ salt.

Purity (LC-MS)

99%+

Package contents

Remdesivir triphosphate salt

This compound is for research use only. We do not sell to patients.

Size	Availability	Price	Quantity
5 mg	In stock	€550	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
10 mg	In stock	€1000	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
25 mg	In stock	€1500	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity
50 mg	In stock	€2500	Remdesivir triphosphate – GS-443902 – CAS 1355149-45-9 quantity

SKU: N/A Category: Antivirotics

Description
Additional information

Characterisation

CAS: 1355149-45-9, 1355050-21-3 (Na⁺ salt)

IUPAC Name: 2-C-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-2,5-anhydro-D-altrononitrile 6-triphosphate

Other names: GS-441524 triphosphate, Remdesivir metabolite, Remdesivir triphosphate metabolite

Molecular weight: 531.21 g/mol, 619.13 g/mol (Na⁺ salt), 935.48 g/mol (Et₃N⁺ salt)

Molecular formula: C₁₂H₁₆N₅O₁₃P₃

Storage: -20 °C, protect from light, stored under argon

We are providing Remdesivir triphosphate in the form of Na⁺ salt or Et₃N⁺ salt.

Description

Remdesivir triphosphate is synthesised by Santiago Lab (Prague, Czech Republic). GS-443902 is the active triphosphate metabolite of Remdesivir with activity against zoonotic feline infectious peritonitis virus (FIPV) and severe acute respiratory syndrome (SARS) virus from Coronaviridae family. GS-443902 (GS-441524 triphosphate) is a potent viral RNA-dependent RNA-polymerases (RdRp) inhibitor with IC₅₀s of 1.1 µM, 5 µM for RSV RdRp and HCV RdRp, respectively.

Remdesivir, developed by Gilead Sciences, is an adenosine prodrug that metabolizes into its active form GS-441524 which interferes with the action of viral RNA-dependent RNA polymerase and evades proofreading by viral exoribonuclease (ExoN), causing a decrease in viral RNA production.

Chemicals are distributed worldwide

Buy Remdesivir triphosphate now, get your order in 48 hours

Shipping through FedEx in EU in 48 hours
When you buy whole AVIROMIX you get shipping in EU for free
All compounds are safely and rigorously packed
For the shipment outside the EU contact us

Payment

We are sending the invoice the same day as the shipment
We are able to modify the invoice for the academic institution, so the order can be paid from grants

References

References
1. Shannon, A.; Le, N. T.-T.; Selisko, B.; Eydoux, C.; Alvarez, K.; Guillemot, J.-C.; Decroly, E.; Peersen, O.; Ferron, F.; Canard, B., Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020, 178, 104793.
2. Ju, J.; Li, X.; Kumar, S.; Jockusch, S.; Chien, M.; Tao, C.; Morozova, I.; Kalachikov, S.; Kirchdoerfer, R. N.; Russo, J. J., Nucleotide analogues as inhibitors of SARS-CoV polymerase. bioRxiv 2020, 1-18.
3. Jordan, P. C.; Liu, C.; Raynaud, P.; Lo, M. K.; Spiropoulou, C. F.; Symons, J. A.; Beigelman, L.; Deval, J., Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase. PLoS Pathogens 2018, 14 (2), e1006889/1-e1006889/23.
4. Siegel, D.; Hui, H. C.; Doerffler, E.; Clarke, M. O.; Chun, K.; Zhang, L.; Neville, S.; Carra, E.; Lew, W.; Ross, B.; Wang, Q.; Wolfe, L.; Jordan, R.; Soloveva, V.; Knox, J.; Perry, J.; Perron, M.; Stray, K. M.; Barauskas, O.; Feng, J. Y.; Xu, Y.; Lee, G.; Rheingold, A. L.; Ray, A. S.; Bannister, R.; Strickley, R.; Swaminathan, S.; Lee, W. A.; Bavari, S.; Cihlar, T.; Lo, M. K.; Warren, T. K.; Mackman, R. L., Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648-1661.
5. Clarke, M. O. N. H.; Jordan, R.; Mackman, R. L.; Ray, A. S.; Siegel, D. Preparation of amino acid-containing nucleosides for treating flaviviridae virus infections. 2017-US28243, 2017184668, 20170419., 2017.
6. Warren, T. K.; Jordan, R.; Lo, M. K.; Ray, A. S.; Mackman, R. L.; Soloveva, V.; Siegel, D.; Perron, M.; Bannister, R.; Hui, H. C.; Larson, N.; Strickley, R.; Wells, J.; Stuthman, K. S.; Van Tongeren, S. A.; Garza, N. L.; Donnelly, G.; Shurtleff, A. C.; Retterer, C. J.; Gharaibeh, D.; Zamani, R.; Kenny, T.; Eaton, B. P.; Grimes, E.; Welch, L. S.; Gomba, L.; Wilhelmsen, C. L.; Nichols, D. K.; Nuss, J. E.; Nagle, E. R.; Kugelman, J. R.; Palacios, G.; Doerffler, E.; Neville, S.; Carra, E.; Clarke, M. O.; Zhang, L.; Lew, W.; Ross, B.; Wang, Q.; Chun, K.; Wolfe, L.; Babusis, D.; Park, Y.; Stray, K. M.; Trancheva, I.; Feng, J. Y.; Barauskas, O.; Xu, Y.; Wong, P.; Braun, M. R.; Flint, M.; McMullan, L. K.; Chen, S.-S.; Fearns, R.; Swaminathan, S.; Mayers, D. L.; Spiropoulou, C. F.; Lee, W. A.; Nichol, S. T.; Cihlar, T.; Bavari, S., Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature (London, United Kingdom) 2016, 531 (7594), 381-385.
7. Chun, B. K.; Clarke, M. O. N. H.; Doerffler, E.; Hui, H. C.; Jordan, R.; Mackman, R. L.; Parrish, J. P.; Ray, A. S.; Siegel, D. Preparation of nucleosides and methods for treating Filoviridae virus infections. 2015-14926062 20160122374, 20151029., 2016.
8. Cho, A.; Saunders, O. L.; Butler, T.; Zhang, L.; Xu, J.; Vela, J. E.; Feng, J. Y.; Ray, A. S.; Kim, C. U., Synthesis and antiviral activity of a series of 1'-substituted 4-aza-7,9-dideazaadenosine C-nucleosides. Bioorganic & Medicinal Chemistry Letters 2012, 22 (8), 2705-2707.

Shop